Compare Five9 Inc (FIVN) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Five9 Inc vs Merck & Co., Inc. — how do they compare? Five9 Inc trades at $36.44 (market cap $2.63B), while Merck & Co., Inc. trades at $145.83 (market cap $351.28B). The key difference: Merck & Co., Inc. is far larger — about 133.6× Five9 Inc's market cap, and Merck & Co., Inc. pays a 2.39% dividend while Five9 Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Five9 Inc for 72 Days and Merck & Co., Inc. for 98 Days on average.
| FIVN | MRK | |
|---|---|---|
Market Cap | $2.63B | $351.28B |
Volume | 1,864,393 | 7,969,665 |
Sector | Technology | Health |
52-Week High | $38.65 | $156.43 |
52-Week Low | $13.61 | $82.49 |
Typical Hold Time | 72 Days | 98 Days |
Enterprise Value | $2.78B | $398.04B |
Dividend Yield | — | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Five9 (FIVN) trades at $35.10, up 3.91% with strong technical momentum near recent highs. The company shows accelerating revenue growth, reaching $1.15B in 2025 with improving profitability (net margin 4.94%). Recent quarters have consistently beaten EPS estimates, while AI revenue surged 78% YoY to $39M in Q2 2026. Analyst sentiment remains bullish with 61% buy ratings and a $34 consensus target.
Outlook remains positive driven by AI contact center adoption and subscription growth, though high valuation multiples (P/E 51.7) and insider selling present near-term risks. The stock's technical setup suggests continued upside if it maintains above $34 support, but investors should monitor debt levels and competitive pressures in the CCaaS space.
Merck (MRK) trades at $145.6, up 1.97% today, with a bearish technical signal but strong fundamental performance. Recent earnings have consistently beaten estimates, and the company is expanding its oncology pipeline through the acquisition of Terns Pharmaceuticals. Revenue growth is steady, with 2025 revenue at $65.01B and net income of $18.25B, though 2026 projections show a significant drop in net income to $3.2B. The stock is supported by a high analyst buy consensus of 68.42% and a price target of $158.78.
The outlook for MRK is mixed; strong earnings beats and strategic acquisitions provide upside potential, but high valuation ratios and a projected earnings decline in 2026 pose risks. Investors should weigh the company's robust profitability and analyst support against execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Five9 Inc
Five9 provides cloud-native contact center software that enables digital customer service, sales, and marketing engagement. The company's Virtual Contact Center platform combines core telephony functionality, omnichannel engagement capabilities, and various software modules into a unified cloud contact-center-as-a-service, or CCaaS, platform. Five9's artificial intelligence and automation portfolio supplements and enhances the firm's core CCaaS offerings, including solutions for digital self-service, agent assist technology, and workflow automation. Five9 also offers workforce optimization products that optimize call center efficiency through workforce management solutions, manage interaction quality, and track agent performance.
Read more on FIVN →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
